Trastuzumab Completed Phase 1 Trials for Neoplasms, Breast Treatment

Indications	Status	Purpose	Phase
DBCOND0030201 (Neoplasms, Breast)	Completed	Treatment	1

clinicaltrials.gov Identifier	Title	Drugs
NCT01265927	A Study Inhibiting Telomerase to Reverse Trastuzumab Resistance in HER2+ Breast Cancer	Grn163l (DB05036) Trastuzumab (DB00072)
NCT01097460	MM-111 in Combination With Herceptin in Patients With Advanced Her2 Amplified, Heregulin Positive Breast Cancer	Trastuzumab (DB00072)
NCT00950742	Phase I Open Label Trial to Assess Safety of BIBW 2992 (Afatinib) in Combination With Herceptin® in Patients With HER2-positive Advanced Breast Cancer.	Afatinib (DB08916) Trastuzumab (DB00072)
NCT00367471	Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer.	Carboplatin (DB00958) Lapatinib (DB01259) Paclitaxel (DB01229) Trastuzumab (DB00072)
NCT00371488	GW572016 Combined With Trastuzumab For The Treatment Of Previously Trastuzumab-Treated Breast Cancer	Lapatinib (DB01259) Trastuzumab (DB00072)
NCT03013881	A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of UB-921 in Healthy Volunteers	Trastuzumab (DB00072)